Hims & Hers Expands Weight-Management Program to the United Kingdom
HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to obesity treatments.
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Expands Its Technology-Driven Personalized Virtual Care
HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.
Hims and Hers to offer weight-loss treatments in UK
Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United Kingdom which will include drugs like Novo Nordisk's Wegovy, the company said on Wednesday.
Hims & Hers Plunges 29.1% in 6 Months: Time to Hold the Stock or Sell?
HIMS expands into Canada and Europe while facing regulatory hurdles and execution risks in weight-loss care.
A New Market, A New Catalyst: Assessing Hims & Hers' Canadian Opportunity
Hims & Hers Health expands into Canada via Livewell acquisition, targeting a large, underserved weight-loss market. Canadian entry leverages local leadership and expertise, aiming to replicate successful European expansion and accelerate subscriber growth. GLP-1 weight-loss treatments drive revenue potential but introduce margin pressure and cost volatility, creating both opportunity and structural risk.
HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency
Hims & Hers is set to acquire YourBio Health, adding bladeless microneedle tech to transform the blood collection experience.
Hims & Hers shares jump on expansion into Canada
US-based digital health company Hims & Hers Holdings Inc (NYSE:HIMS) is entering the Canadian market following its acquisition of Livewell, a Canadian telehealth platform focused on weight loss and other wellness services. The move positions Hims & Hers to launch a Canadian weight loss program in 2026, coinciding with the availability of the first generic semaglutide.
Hims & Hers Expands Care Scope as Prescription Platforms Evolve
HIMS grows its telehealth-to-prescription model with new offerings in weight loss, hormone care and diagnostics.
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside?
Hims & Hers and GoodRx are reshaping virtual care, but which one leads in platform strategy and patient engagement? Let's dive in.
Hims & Hers Expands Care Scope as Digital Health Platforms Evolve
HIMS expands into low testosterone and menopause care, with plans for longevity and global growth in 2026.
